Across TCGA pan-cancer cohorts, RNU6-886P RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RNU6-886P’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where RNU6-886P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6-886P is over-expressed in tumor.

PRAD, LUAD, and BRCA are the cancer types where RNU6-886P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-886P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.271	.006	2	view →
LUAD	All	All	+0.183	.032	1	view →
BRCA	All	II,III,IV	+0.152	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RNU6-886P RNA expression & survival · all RNU6-886P data types